Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine Plus Camrelizumab in HER2-Negative Advanced Gastric Cancer
NCT04508686Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab and capecitabine in gastric cancer (GC), gastroesophageal junction adenocarcinoma and Cervical Cancer (CC), sponsored by Ruijin Hospital. Primary endpoint: Adverse Events as Assessed by CTCAE v5.0 at 48 months. Status: unknown.
02
Drugs
camrelizumabcapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaCervical Cancer (CC)
Beyond the preview
Go deeper on NCT04508686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508686.